A previously reported deficiency of "total" pyruvate dehydrogenase complex activity is further characterized. Dihydrolipoyl transacetylase (E2) and lipoamide dehydrogenase (E3) activities in the patient's fibroblasts were normal. Pyruvate dehydrogenase activity (El) was 33% of that in fibroblasts from an age-matched control. The amounts of each of the components of pyruvate dehydrogenase complex were analyzed using an immunoblot technique and specific antibodies. Levels of components E2 and E3 were the same in fibroblasts from the patient and control, confirming the activity measurements. However, the levels of Ela and Elft were reduced markedly in fibroblasts from the patient. Thus, impairment in the pyruvate dehydrogenase complex activity was due to a reduction in the amount of the El component of the complex.
Introduction
Genetic defects involving the enzymes of pyruvate metabolism, pyruvate dehydrogenase complex (PDHC),' pyruvate carboxylase, lactate dehydrogenase, and P-enolpyruvate carboxykinase, are reported frequently (for review, see [1] [2] [3] [4] . The most common of these involves the PDHC (1-3). However, characterizations of the defects involving this complex have been limited to the measurements of the enzymatic activities of the complex and its components in extracts of skin fibroblasts, and in very rare cases, extracts of other tissues from affected patients. PDHC is composed of three catalytic components, pyruvate dehydrogenase (El) ( specific kinase inactivates El (and hence the complex) while dephosphorylation by its phosphatase restores catalytic activity of the complex (5) . The presence ofan additional polypeptide (relative molecular mass [Mr] , 50,000) in mammalian PDHC (6) , has been established using immunological as well as structural analyses (7, 8) .
Classification 
Methods
Patient. A detailed case history ofthe patient (J.S.) was reported recently (9) . Significant findings included lactic acidemia, intermittent ataxia, moderate psychomotor retardation, opthalmoplegia, and retinal pigment epithelial changes. A central hypoventilation syndrome also was documented. On postmortem histopathologic examination, the brain was shown to exhibit the specific central nervous system pathology ofLeigh's disease (10) . Deficiency of PDHC was established by measuring "total" PDHC activity in disrupted skin fibroblasts after pretreatment with dichloroacetate (1 1).
Assays for the complex and its catalytic components. Human skin fibroblasts were grown in Eagle's minimum essential medium, basically as described (1 1 Immunological identification ofE,, E2, and E3 ofPDHC. Human skin fibroblasts in culture were harvested by scraping with a rubber policeman. Cells were washed twice with ice-cold phosphate-buffered saline, and crude mitochondrial pellets were prepared using digitonin (14) . Whole cells or crude mitochondrial pellets were stored at -760C. PDHC components were characterized by Western blot analysis. Frozen cells or mitochondrial pellets were resuspended in ice-cold 20 mM potassium phosphate, pH 7.0, 1% Triton X-100. The samples were sonicated twice for 10 s at continuous pulse with a microtip and were dissociated by boiling for 10 min in 17 mM dithiothreitol, 2% sodium dodecyl sulfate (SDS). The samples were separated by electrophoresis in discontinuous SDS polyacrylamide gels (6% polyacrylamide stacking, 9% polyacrylamide separation).
Proteins were transferred to a nylon-based membrane (Zeta-probe, Bio-Rad Laboratories, Richmond, CA) using a Bio-Rad transblot apparatus essentially as described in Bio-Rad Instruction Manual #85-0176-485, except that electroelution was conducted at room temperature at 75 mA, constant current, for 8 h. After transfer, the membrane was incubated with a specific antibody followed by '25I-protein A. Immunoreactive proteins were visualized by exposing the membrane to XOmat AR film (Eastman Kodak Co., Rochester, NY). In preliminary experiments using 1251I-labeled El (15) from bovine kidney, both a-subunit and a-subunit were quantitatively transferred to the Zeta-probe membrane. Based on staining of the gel with Coomassie Brilliant Blue R-250 after electrotransfer, electrotransfers of E2 and E3 also were quantitative using these conditions. Preliminary experiments showed that E2 is highly susceptible to proteolytic degradation. Proteolysis was minimized by including protease inhibitors in the solutions during the preparation and solubilization of the mitochondrial fraction (results not shown). The following mixture of protease inhibitors was found to be effective in minimizing E2 degradation: (final concentration) 2 mM EDTA, 2 mM EGTA, 0.2 mM phenylmethenesulfonyl fluoride, 0.5 mg/liter Leupeptin, and 0.7 mg/ liter Pepstatin.
Rabbit antisera against individual components El (16), E2 (16) , and E3 (17) of PDHC were raised using highly purified bovine kidney El, bovine heart E2, and a commercially available E3 preparation from porcine heart (Sigma Chemical Co., St. Louis, MO). The anti-E3 serum reacts with not only the E3 component of PDHC, but also the E3 components of a-ketoglutarate and branched-chain ketoacid dehydrogenase complexes. In contrast, the anti-E2 serum reacts only with the E2 component of PDHC (Carothers, D. J., and M. S. Patel, unpublished observations). For immunoblot analyses, antisera were diluted with 20 mM Trizma base, 500 mM NaCI, pH 7.5, 5% bovine serum albumin. Antisera for El, E2, and E3 were diluted 20-fold, 50-fold, and 50-fold, respectively.
Results
"Total" PDHC activity (dichloroacetate-activated) in extracts of fibroblasts from patient J.S. was considerably lower than that observed in the fibroblasts from three age-matched controls (F, P.H., and C.S.) and a younger control (B.M.) (Table I) , confirming our earlier report (9) . Treatment of the extract of fibroblasts from patient J.S. with added purified pyruvate dehydrogenase phosphatase caused a degree of activation of the PDHC equal to that caused by dichloroacetate, Mg++ and Ca`(9), indicating that the phosphatase activity in the patient's fibroblasts was normal and suggesting that the low PDHC activity in these fibroblasts was due to a defect in one of the other components.
To determine which component of the PDHC was affected, the enzymatic activities of the El, E2, and E3 components of the complex were assayed. E2 and E3 activities of the patient's fibroblasts were not significantly different from those of an agematched control (F) ( (Fig. 1, panel 1) . Skin fibroblasts from patient J.S., therefore, contained normal quantities of E3. A similar analysis established that the mutant fibroblast contained normal amounts of immunoreactive E2 (Fig. 1, panel 2) . The relative amounts of Ela and E1# were analyzed in mitochondrial pellets derived from equal quantities offibroblasts from the two age-matched controls (P.H. and C.S.) and patient J.S. (Fig. 1, panel 3) . Fibroblasts from two controls had similar amounts ofimmunoreactive pro- In a separate experiment (Fig. 2) , amounts of El subunits were analyzed in extracts ofwhole cell (right) and isolated mitochondria (left). The amounts of immunoreactive proteins at the positions corresponding to Ela and El# are drastically decreased lecular weight heavier than their respective mature peptides (Raefsky, C., and M. S. Patel, unpublished observations). In the present study (Fig. 2, right) , no precursor peptides of either E Ia or El, were detected from whole cell extracts of the patient's fibroblasts. A point mutation should theoretically affect only one ofthe subunits. However, a defect in one ofthe two peptides of El might inhibit transport of mutated precursor-peptide into the mitochondria or assembly ofthe heterotetramer (a2#2), leading to rapid degradation of one or both subunits. Studies using specific cDNA probes and in vitro translation are needed to establish the nature of the defect of E, in this patient.
In summary, an impairment in the PDHC activity in this patient is attributable to a reduction in the amount of the El component of the complex. The immunoblot technique employed in this study should prove useful in identifying defects in the PDHC components in fibroblasts from a large number of patients.
